Group 1 - The company will hold its annual general meeting on May 16, 2025, with both on-site and online voting options available for shareholders [1][2] - The agenda includes the reappointment of Huaxing Accounting Firm as the auditing institution for the fiscal year 2025 and a proposal to repurchase and cancel certain restricted stocks [1][2][3] - The meeting will be presided over by the chairman, Liu Jianhua, and will include reports on the 2024 annual report and the board's work report [2][3] Group 2 - The company reported a significant decline in net profit for 2024, amounting to 42.2167 million yuan, a decrease of 71.94% year-on-year, primarily due to goodwill impairment related to the "Mige Xi" asset group [8][18] - The total assets of the company as of December 31, 2024, were 3.9197 billion yuan, reflecting a 3.67% increase compared to the previous year [18][20] - The total liabilities increased by 17.94% to 493.5249 million yuan, with short-term borrowings rising by 45.42% [20][21] Group 3 - The company plans to distribute a cash dividend of 6.00 yuan per 10 shares for the fiscal year 2024, with a total share capital of 159,356,477 shares [22][23] - The company aims to enhance investor relations through various communication channels and regular performance briefings [10][11] - The board of directors will continue to strengthen corporate governance and compliance with regulatory requirements in 2025 [10][11][12]
康辰药业: 康辰药业2024年年度股东大会会议资料